Literature DB >> 29343435

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.

Fei Zhao1, Christine Xiao1, Kathy S Evans1, Tbalamayooran Theivanthiran1, Nicholas DeVito1, Alisha Holtzhausen2, Juan Liu3, Xiaojing Liu3, David Boczkowski4, Smita Nair4, Jason W Locasale3, Brent A Hanks5.   

Abstract

Despite recent advances, many cancers remain refractory to available immunotherapeutic strategies. Emerging evidence indicates that the tolerization of local dendritic cells (DCs) within the tumor microenvironment promotes immune evasion. Here, we have described a mechanism by which melanomas establish a site of immune privilege via a paracrine Wnt5a-β-catenin-peroxisome proliferator-activated receptor-γ (PPAR-γ) signaling pathway that drives fatty acid oxidation (FAO) in DCs by upregulating the expression of the carnitine palmitoyltransferase-1A (CPT1A) fatty acid transporter. This FAO shift increased the protoporphyrin IX prosthetic group of indoleamine 2,3-dioxgenase-1 (IDO) while suppressing interleukin(IL)-6 and IL-12 cytokine expression, culminating in enhanced IDO activity and the generation of regulatory T cells. We demonstrated that blockade of this pathway augmented anti-melanoma immunity, enhanced the activity of anti-PD-1 antibody immunotherapy, and suppressed disease progression in a transgenic melanoma model. This work implicates a role for tumor-mediated metabolic reprogramming of local DCs in immune evasion and immunotherapy resistance.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Wnt5a; dendritic cell tolerization; fatty acid oxidation; immune evasion; immunotherapy resistance; indoleamine 2,3-dioxygenase; melanoma microenvironment; protoporphyrin IX; regulatory T cells; β-catenin

Mesh:

Substances:

Year:  2018        PMID: 29343435      PMCID: PMC5777287          DOI: 10.1016/j.immuni.2017.12.004

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   43.474


  39 in total

1.  Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation.

Authors:  Connie M Krawczyk; Thomas Holowka; Jie Sun; Julianna Blagih; Eyal Amiel; Ralph J DeBerardinis; Justin R Cross; Euihye Jung; Craig B Thompson; Russell G Jones; Edward J Pearce
Journal:  Blood       Date:  2010-03-29       Impact factor: 22.113

Review 2.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

3.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

4.  The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells.

Authors:  Emmelie A Jansson; Alexandra Are; Gediminas Greicius; I-Chun Kuo; Denise Kelly; Velmurugesan Arulampalam; Sven Pettersson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

5.  The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Sylvaine You; Barbara C McGrath; Douglas R Cavener; Carmine Vacca; Ciriana Orabona; Roberta Bianchi; Maria L Belladonna; Claudia Volpi; Pere Santamaria; Maria C Fioretti; Paolo Puccetti
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

Review 6.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Lipid accumulation and dendritic cell dysfunction in cancer.

Authors:  Donna L Herber; Wei Cao; Yulia Nefedova; Sergey V Novitskiy; Srinivas Nagaraj; Vladimir A Tyurin; Alex Corzo; Hyun-Il Cho; Esteban Celis; Brianna Lennox; Stella C Knight; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Scott Antonia; Mayer Fishman; Robert L Ferris; Valerian E Kagan; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2010-07-11       Impact factor: 53.440

8.  SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis.

Authors:  Ciriana Orabona; Maria T Pallotta; Claudia Volpi; Francesca Fallarino; Carmine Vacca; Roberta Bianchi; Maria L Belladonna; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

9.  Development and quantitative evaluation of a high-resolution metabolomics technology.

Authors:  Xiaojing Liu; Zheng Ser; Jason W Locasale
Journal:  Anal Chem       Date:  2014-01-28       Impact factor: 6.986

10.  WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism.

Authors:  Victoria Sherwood; Shivendra Kumar Chaurasiya; Elin J Ekström; William Guilmain; Qing Liu; Tomas Koeck; Kate Brown; Karin Hansson; Margrét Agnarsdóttir; Michael Bergqvist; Karin Jirström; Fredrik Ponten; Peter James; Tommy Andersson
Journal:  Carcinogenesis       Date:  2013-11-30       Impact factor: 4.944

View more
  76 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

2.  Cell-Intrinsic Wnt4 Influences Conventional Dendritic Cell Fate Determination to Suppress Type 2 Immunity.

Authors:  Li-Yin Hung; John L Johnson; Yingbiao Ji; David A Christian; Karl R Herbine; Christopher F Pastore; De'Broski R Herbert
Journal:  J Immunol       Date:  2019-06-07       Impact factor: 5.422

Review 3.  Immunometabolism: A new target for improving cancer immunotherapy.

Authors:  Chunqing Guo; Shixian Chen; Wenjie Liu; Yibao Ma; Juan Li; Paul B Fisher; Xianjun Fang; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 4.  Role of dendritic cell metabolic reprogramming in tumor immune evasion.

Authors:  Michael P Plebanek; Michael Sturdivant; Nicholas C DeVito; Brent A Hanks
Journal:  Int Immunol       Date:  2020-06-26       Impact factor: 4.823

Review 5.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

Review 6.  Wnts and the hallmarks of cancer.

Authors:  Zheng Zhong; Jia Yu; David M Virshup; Babita Madan
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

7.  TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.

Authors:  Alisha Holtzhausen; William Harris; Eric Ubil; Debra M Hunter; Jichen Zhao; Yuewei Zhang; Dehui Zhang; Qingyang Liu; Xiaodong Wang; Douglas K Graham; Stephen V Frye; H Shelton Earp
Journal:  Cancer Immunol Res       Date:  2019-08-26       Impact factor: 11.151

8.  Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas.

Authors:  Nivea Dias Amoedo; Saharnaz Sarlak; Emilie Obre; Pauline Esteves; Hugues Bégueret; Yann Kieffer; Benoît Rousseau; Alexis Dupis; Julien Izotte; Nadège Bellance; Laetitia Dard; Isabelle Redonnet-Vernhet; Giuseppe Punzi; Mariana Figueiredo Rodrigues; Elodie Dumon; Walid Mafhouf; Véronique Guyonnet-Dupérat; Lara Gales; Tony Palama; Floriant Bellvert; Nathalie Dugot-Senan; Stéphane Claverol; Jean-Marc Baste; Didier Lacombe; Hamid Reza Rezvani; Ciro Leonardo Pierri; Fatima Mechta-Grigoriou; Matthieu Thumerel; Rodrigue Rossignol
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 9.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

10.  The signaling protein Wnt5a promotes TGFβ1-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap/Taz.

Authors:  Ye Feng; Yan Liang; Xingwen Zhu; Mingjie Wang; Yuan Gui; Qingmiao Lu; Mengru Gu; Xian Xue; Xiaoli Sun; Weichun He; Junwei Yang; Randy L Johnson; Chunsun Dai
Journal:  J Biol Chem       Date:  2018-10-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.